glp-1 receptors Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1R and Diabetes

Weight-Loss Care Trends: Certifications, Mental Health, and the Push for Oral GLP-1s: Certifications: Despite 81% reporting prescribing any medications for weight loss or a weight loss benefit in the past year, 67% of those surveyed report not having any Obesity Treatment Certification, such as the American Board of Obesity Medicine or European Association Study of Obesity Medicine

Not approved for human or animal use under any circumstances

doi: 10.2337/db14-0302 37 BurmeisterMAAyalaJDruckerDJAyalaJE

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

Ozempic Blindness Lawsuit Overview Ozempic blindness lawsuits claim that the drugs manufacturer, Novo Nordisk, failed to adequately warn consumers about the risk of vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)